The Only Technology Available in Products Proven to Reduce over 99.9% of the Virus that Causes COVID-19 on Both Surfaces and In the Air


ActivePure does not replace the need to follow CDC guidance and should be used as a complementary technology.

Back to School.
Back in Business.
Back to Life.


ActivePure Technology is proven to neutralize pathogens1. including the virus that causes COVID-19, on surfaces and in the air. ActivePure does not replace the need to follow CDC guidance and should be used as. complementary technology. Our Medical Guardian is cleared by the FDA as a Class II Medical Device; and now we are making this same technology available to every business, hospital, public space, school, and home in America.



Safe, Tested, Trusted


Since 1924, ActivePure Technologies has created the healthiest indoor environments across the globe. Our ActivePure Technology, which evolved from the NASA space program, has undergone continuous research and development efforts to continuously improve its efficacy in various applications since 2009.

Products developed by ActivePure Technologies have helped protect over 50 million businesses and residences worldwide in more than 72 counties. Our technology has been honored by the Smithsonian, the Space Foundation as Certified Space Technology, and has been inducted into the Space Foundation Hall of Fame.


In extensive independent lab testing, ActivePure® Technology has been proven to significantly reduce the following contaminants and pathogens. ActivePure testing is always done in independent, FDA-compliant laboratories to ensure accurate and unbiased results.

  • SARS-CoV-2 - RNA Virus
  • H1N1 Influenza
  • H5N8 Influenza
  • Murine Norovirus
  • PhiX-174
  • MS2 Bacteriophage
  • MRSA
  • E. coli
  • Salmonella enterica
  • Legionella pneumophila
  • Clostridium difficile
  • Bacillus globigii
  • Erwinia herbicola
  • Listeria monocytogenes
  • Botrytis cinerea
  • Candida auris
  • Sclerotinia sclerotiorum
  • Aspergillus versicolor
  • Aspergillus niger endospores
  • Methicillin-resistant Staphylococcus epidermis
  • Staphylococcus epidermidi


ActivePure and FDA


In June 2020, the ActivePure Medical Guardian with ActivePure Technology was registered and cleared as an FDA Class II Medical Device after a two-year process. The product cleared by the FDA is intended for medical purposes and is used to reduce staphylococcus epidermidis and erwinia herbicola bacteria; MS2 and Phi-X174 viruses; aspergillus niger fungal spores; and bacillus globigii bacterial spores from the air in a temperature-controlled professional health care environment.


ActivePure is Proven Safe Around People, Pets, and Plants

ActivePure Technology begins working immediately to disinfect exposed surfaces and the air safely. The FDA validated ActivePure Technology's safety for use in occupied spaces in 2020, with the ActivePure Medical Guardian becoming an FDA Cleared Class II Medical Device. The same technology in the ActivePure Medical Guardian is available in over 100 different portable, handheld, and HVAC installed units, which run quietly, 24 hours a day, seven days a week.

Devices with ActivePure Technology release millions of safe microscopic ActivePure Molecules into rooms. These molecules continuously seek airborne and surface pathogens and contaminants and immediately neutralize them on impact.

Real-time disinfection is critical for indoor high-occupancy areas. ActivePure Technology is the best solution to get the world back to work, school, restaurants, events and life before COVID-19.


ActivePure and SARS-CoV-2 viruses


ActivePure Technology is the most effective surface and air countermeasure to viruses and bacteria, with its efficacy based and proven in independent university and FDA-compliant laboratory studies. ActivePure Technology has consistently proven its ability to safely control and neutralize contaminants such as viruses, bacteria, mold, fungi, and Volatile Organic Compounds (VOCs) in numerous independent studies.1
Notably:
  • University of Texas Medical Branch confirmed that the ActivePure Technology inside the Aerus Pure & Clean and the Vollara Air & Surface Pro inactivates 99.9% of airborne SARS-CoV-2 viruses within three minutes
  • The Aerus Hydroxyl Blaster with ActivePure Technology demonstrated in an FDA-compliant laboratory, MRIGlobal, a 93% surface reduction in three hours of live SARS-CoV-2 viruses and a 99.98% reduction rate in seven hours





ActivePure and Cleveland Clinic


ActivePure Medical recently began a two-year clinical trial with the Cleveland Clinic to study ActivePure's impact on surgical site infections. The trial is restricted to adults aged 18 years or older, having surgery lasting at least one hour. Patients with present-on-admission infections are excluded from the study. Operating rooms are randomized in one month blocks to ActivePure air sterilization or conventional air handling. A minimum of 67,653 patients with a maximum of 86,639 patients are needed for this study.